Biogen (NASDAQ: BIIB) reported Q4 EPS of $3.44, $0.03 better than the analyst estimate of $3.41. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.41 billion.

GUIDANCE:

Biogen sees FY2025 EPS of $15.25-$16.25, versus the consensus of $16.24.

For earnings history and earnings-related data on Biogen (BIIB) click here.